Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_assertion type Assertion NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_head.
- NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_assertion description "[We now show that the combination of A-357300 with cyclophosphamide at the maximal tolerated dose sustained tumor regression with a T/C at day 48 of 0.16 (P < 0.001) in the CHP-134 xenograft model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_provenance.
- NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_assertion evidence source_evidence_literature NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_provenance.
- NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_assertion SIO_000772 15814649 NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_provenance.
- NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_assertion wasDerivedFrom befree-2016 NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_provenance.
- NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_assertion wasGeneratedBy ECO_0000203 NP488817.RABv9JzslyqMTBhiZpOcVkth38S3x5vpZL9syMFWuMO48130_provenance.